{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:26:23Z","timestamp":1784204783257,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vaccines against enteric diseases could improve global health. Despite this, only a few oral vaccines are currently available for human use. One way to facilitate such vaccine development could be to identify a practical and relatively low cost biomarker assay to assess oral vaccine induced primary and memory IgA immune responses in humans. Such an IgA biomarker assay could complement antigen-specific immune response measurements, enabling more oral vaccine candidates to be tested, whilst also reducing the work and costs associated with early oral vaccine development. With this in mind, we take a holistic systems biology approach to compare the transcriptional signatures of peripheral blood mononuclear cells isolated from volunteers, who following two oral priming doses with the oral cholera vaccine Dukoral\u00ae, had either strong or no vaccine specific IgA responses. Using this bioinformatical method, we identify <jats:italic>TNFRSF17<\/jats:italic>, a gene encoding the B cell maturation antigen (BCMA), as a candidate biomarker of oral vaccine induced IgA immune responses. We then assess the ability of BCMA to reflect oral vaccine induced primary and memory IgA responses using an ELISA BCMA assay on a larger number of samples collected in clinical trials with Dukoral\u00ae and the oral enterotoxigenic <jats:italic>Escherichia coli<\/jats:italic> vaccine candidate ETVAX. We find significant correlations between levels of BCMA and vaccine antigen-specific IgA in antibodies in lymphocyte secretion (ALS) specimens, as well as with proportions of circulating plasmablasts detected by flow cytometry. Importantly, our results suggest that levels of BCMA detected early after primary mucosal vaccination may be a biomarker for induction of long-lived vaccine specific memory B cell responses, which are otherwise difficult to measure in clinical vaccine trials. In addition, we find that ALS-BCMA responses in individuals vaccinated with ETVAX plus the adjuvant double mutant heat-labile toxin (dmLT) are significantly higher than in subjects given ETVAX only. We therefore propose that as ALS-BCMA responses may reflect the total vaccine induced IgA responses to oral vaccination, this BCMA ELISA assay could also be used to estimate the total adjuvant effect on vaccine induced-antibody responses, independently of antigen specificity, further supporting the usefulness of the assay.<\/jats:p>","DOI":"10.3389\/fimmu.2021.647873","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T04:58:05Z","timestamp":1616389085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans"],"prefix":"10.3389","volume":"12","author":[{"given":"Lynda","family":"Mottram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Mari","family":"Svennerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/21645515.2019.1611200","article-title":"Vaccines for enteric diseases","volume":"15","author":"Cohen","year":"2019","journal-title":"Human vaccines and immunotherapeutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20150142","DOI":"10.1098\/rstb.2015.0142","article-title":"Vaccines against enteric infections for the developing world","volume":"370","author":"Czerkinsky","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1586\/erv.12.12","article-title":"Recent progress toward an enterotoxigenic Escherichia coli vaccine","volume":"11","author":"Svennerholm","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2013.058","article-title":"Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood","volume":"8","author":"Saletti","year":"2013","journal-title":"Nat Protoc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.vaccine.2016.11.055","article-title":"Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country","volume":"35","author":"Akhtar","year":"2017","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1016\/j.vaccine.2013.04.066","article-title":"Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: a tool for assessing immunological memory","volume":"31","author":"Leach","year":"2013","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1016\/j.vaccine.2019.01.016","article-title":"How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions","volume":"37","author":"Mottram","year":"2019","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imm.13012","article-title":"Systems vaccinology and big data in the vaccine development chain","volume":"156","author":"Raeven","year":"2019","journal-title":"Immunology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans","volume":"12","author":"Nakaya","year":"2011","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.immuni.2012.12.008","article-title":"Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines","volume":"38","author":"Obermoser","year":"2013","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fimmu.2018.00564","article-title":"Adjuvant-associated peripheral blood mRNA profiles and kinetics induced by the adjuvanted recombinant protein candidate tuberculosis vaccine M72\/AS01 in Bacillus Calmette-Gu\u00e9rin-vaccinated adults","volume":"9","author":"van den Berg","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3389\/fimmu.2019.00965","article-title":"Survival of long-lived plasma cells (LLPC): piecing together the puzzle","volume":"10","author":"Lightman","year":"2019","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1038\/s41598-018-20740-3","article-title":"Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory","volume":"8","author":"C\u00e1rdeno","year":"2018","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1016\/j.vaccine.2016.04.055","article-title":"Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine","volume":"34","author":"Lundgren","year":"2016","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.vaccine.2019.10.050","article-title":"Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial","volume":"38","author":"Mottram","year":"2020","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1021\/bc2001984","article-title":"Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines","volume":"22","author":"Xu","year":"2011","journal-title":"Bioconjug Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1016\/j.vaccine.2018.11.040","article-title":"Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses","volume":"37","author":"Akhtar","year":"2019","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(03)00226-6","article-title":"CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays","volume":"278","author":"Kreher","year":"2003","journal-title":"J Immunol Methods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","article-title":"Quality control and preprocessing of metagenomic datasets","volume":"27","author":"Schmieder","year":"2011","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12859-017-1559-2","article-title":"Reactome pathway analysis: a high-performance in-memory approach","volume":"18","author":"Fabregat","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1387\/ijdb.103106gs","article-title":"Hematopoietic stem cell emergence in the conceptus and the role of Runx1","volume":"54","author":"Swiers","year":"2010","journal-title":"Int J Dev Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/mi.2016.59","article-title":"The human intestinal B-cell response","volume":"9","author":"Spencer","year":"2016","journal-title":"Mucosal Immunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1016\/j.vaccine.2016.02.076","article-title":"Status of vaccine research and development for enterotoxigenic Escherichia coli","volume":"34","author":"Bourgeois","year":"2016","journal-title":"Vaccine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.4049\/jimmunol.175.5.2814","article-title":"B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells","volume":"175","author":"Yang","year":"","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/mi.2013.64","article-title":"Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy","volume":"7","author":"Gustafson","year":"2014","journal-title":"Mucosal Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e00215","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","article-title":"Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA\/I, CS3, CS5 and CS6 combined with a hybrid LT\/CT B subunit antigen, administered alone and together with dmLT adjuvant","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.647873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T04:58:08Z","timestamp":1616389088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.647873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2021.647873"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.647873","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"article-number":"647873"}}